Effects of Imatinib Mesylate in Polycythemia Vera

Key facts

Sponsor

Niguarda Hospital

Principal Investigator

Enrica Morra, MD

Divisione di Ematologia - Ospedale Niguarda Ca' Granda

Intervention

Imatinib Mesylate(drug)

Enrollment

9 target

Eligibility

18 years · All sexes

Timeline

2007 – 2012

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Polycythemia vera

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07362225
  MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
  MPN Research Foundation
• RECRUITINGPHASE2NCT07232290
  Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
  Chengdu Zenitar Biomedical Technology Co., Ltd
• RECRUITINGPHASE2NCT06985147
  A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
  Disc Medicine, Inc
• RECRUITINGNCT06743035
  Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
  iOMEDICO AG
• RECRUITINGNCT06752941
  LOW-PV Continuation
  FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
• RECRUITINGPHASE3NCT06093672
  Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
  Italfarmaco
• RECRUITINGPHASE1NCT06752746
  A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
  Mabwell (Shanghai) Bioscience Co., Ltd.
• ACTIVE NOT RECRUITINGPHASE3NCT06033586
  Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
  Protagonist Therapeutics, Inc.

See all trials for Polycythemia vera →